Acute aldosterone antagonism improves cardiac vagal control in humans  by Fletcher, Janine et al.
A
I
J
H
J
B
T
a
b
w
g
“
r
t
a
h
a
i
o
b
a
w
i
b
f
s
h
B
U
U
a
Journal of the American College of Cardiology Vol. 43, No. 7, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.058Pharmacology
cute Aldosterone Antagonism
mproves Cardiac Vagal Control in Humans
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OBJECTIVES We have examined the acute effects (45 min) of aldosterone antagonism on heart rate
variability and baroreflex sensitivity, markers of cardiac vagal control, in 13 healthy subjects.
BACKGROUND Evidence for the beneficial effects of aldosterone antagonists comes from studies showing
increased survival rates following their addition to standard heart failure therapy. Many
mechanisms have been suggested for this action, including effects upon the autonomic
nervous system.
METHODS Heart rate variability and baroreflex sensitivity were examined 30 min following the administration
of potassium canrenoate (intravenous) (aldosterone antagonist) or saline (control).
RESULTS Active treatment reduced resting heart rate (6  1 beats/min [mean  standard error
mean]) compared to control (0  1 beat/min) (p  0.001) and increased measures of high
frequency (HF) heart rate variability. Root mean square of successive RR interval differences
increased by 21  5 ms versus 6  5 ms control (p 0.001); HF power increased by 1,369
 674 ms2with aldosterone antagonism compared to 255  431 ms2 following saline
infusion (p  0.01). Baroreflex sensitivity (alpha-HF) was increased after active treatment
(4  2 ms/mm Hg vs. 0  1 ms/mm Hg control [p  0.05]). No changes in plasma
potassium levels were observed.
CONCLUSIONS These results provide evidence that aldosterone antagonists acutely improve cardiac vagal
control, irrespective of any diuretic effects, and may in part explain their beneficial effects in
treatment of heart failure. (J Am Coll Cardiol 2004;43:1270–5) © 2004 by the American
College of Cardiology Foundatione
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She adverse effects of activation of the renin-angiotensin-
ldosterone system in congestive heart failure are evidenced
y the beneficial prognostic effects of blockade of the system
ith angiotensin-converting enzyme inhibitors (1–3). An-
iotensin II has traditionally been viewed as the major
culprit” effector of this system, exerting potentially delete-
ious cardiovascular effects (4–6). However, this octapep-
ide also stimulates the release of aldosterone (7), which
ppears to play an important role in the pathophysiology of
eart failure. In patients with severe heart failure who were
lready established with angiotensin-converting enzyme
nhibitor therapy, the RALES study showed that inhibition
f aldosterone with spironolactone reduces the risk of death
y 30% compared to placebo (8). The beneficial effects of
ldosterone inhibition have also been confirmed in patients
ith impaired left ventricular function after myocardial
nfarction (9). There are a number of potential mechanisms
y which aldosterone might contribute to mortality in heart
ailure, including the retention of sodium, loss of magne-
ium and potassium, the promotion of left ventricular
ypertrophy and fibrosis, vascular fibrosis, and adverse
From the *Department of Physiology, University of Birmingham, Edgbaston,
irmingham, United Kingdom; and †Department of Cardiovascular Medicine,
niversity of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham,
nited Kingdom. The first two authors contributed equally to the study.
Manuscript received June 24, 2003; revised manuscript received October 7, 2003,(ccepted October 13, 2003.ffects on endothelial function (10–17). In addition, aldo-
terone exerts adverse effects on cardiac autonomic control,
ncluding a reduction in the sensitivity of the human
aroreceptor reflex (18). The independent relationship be-
ween impaired cardiac autonomic control and prognosis in
isease states such as heart failure suggests that high levels
f sympathetic activity and reduced vagal control may exert
irect deleterious effects (19). Clinical studies have demon-
trated that in heart failure patients, chronic treatment with
pironolactone improves cardiac autonomic control mea-
ured by heart rate variability (11,20), providing a further
ossible explanation for the prognostic effects of this treat-
ent. These studies could not, however, exclude the possi-
ility that the improved heart rate variability was secondary
o the beneficial hemodynamic effects of spironolactone
diuresis and decreased volume load) rather than any direct
euronal or receptor-mediated effects.
We have investigated the effects of acute aldosterone
eceptor blockade upon cardiac vagal control in healthy
ubjects by measuring heart rate variability and baroreflex
ensitivity responses to a single intravenous dose of potas-
ium canrenoate.
ETHODS
ubjects. Thirteen healthy male volunteers age 18 to 34
mean 27) years were studied. All subjects were in good
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April 7, 2004:1270–5 Aldosterone Antagonism and Cardiac Vagal Controlealth with no history of cardiovascular or other disease, and
ll were normotensive (supine cuff blood pressure measure-
ent140/90 mm Hg during an initial screening visit). No
ubject was taking any medication. This study was carried
ut in accordance with the Declaration of Helsinki (1989)
f the World Medical Association and was approved by the
outh Birmingham Local Research Ethics Committee.
ritten informed consent was obtained before study entry.
xperimental protocol and study design. The study used
random-order, double-blind, placebo-controlled crossover
rotocol. Subjects were studied at the same time of day on
wo separate occasions with at least one week between
tudies. Experiments took place in a quiet, temperature-
ontrolled autonomic function laboratory. The ambient
emperature of the laboratory was maintained at 24  1°C.
ubjects were instructed to abstain from food or drink for at
east 2 h before the experiment and from alcoholic or
affeinated beverages for 24 h. At an initial acclimatization
isit, subjects were trained to breathe at a fixed rate using an
udio signal that was adjusted to suit each individual’s
espiratory frequency.
Subjects were studied in the semisupine position on a
ouch. Venous cannulae were inserted into an antecubital
ein for collection of blood samples and for drug adminis-
ration. A standard three-lead electrocardiogram signal was
mplified, processed (HF signal noise filter 500 Hz), and
igitized at 500 Hz (National Instruments Corporation,
nalogue-to-digital converter board, Austin, Texas). A con-
inuous arterial pressure signal was obtained using the
ortapres device (TNO Biomedical Instrumentation, Am-
terdam, the Netherlands) and was similarly digitized. In
ddition, brachial artery pressure was measured by intermit-
ent cuff sphygmomanometry using an automated oscillo-
etric system (Omron 711, Vernon Hills, Illinois, mean of
recordings). Respiratory movement was recorded from the
mplified output of a strain gauge attached to an elastic
trap around the chest. All digitized signals were displayed
n the screen of a personal computer running LabVIEW
.0 software (National Instruments Corporation). Subjects
ere rested for a 30-min period before the collection of data
o allow hemodynamic stabilization. Two baseline record-
ngs of at least 256 consecutive RR intervals together with
lood pressure and respiratory measurements were acquired
t fixed rate respiration.
Abbreviations and Acronyms
HF  high frequency
LF  low frequency
MR  mineralocorticoid receptors
NO  nitric oxide
pNN50  percentage of successive RR interval
differences exceeding 50 ms
RMSSD  root mean square of successive RR interval
differences
SDNN  standard deviation of RR interval valuesSubjects were randomly assigned to intravenous infusions
f the aldosterone antagonist potassium canrenoate (200 mg
n 100 ml N-saline) (Roche, Welwyn Garden City, Hert-
ordshire, U.K.) or N-saline (100 ml) given over 5 min
uring the first of two studies. The other agent was given
uring a second study 7 to 14 days later.
After 30 min, when the active metabolite of potassium
anrenoate, canrenone, is at its highest plasma concentra-
ion (21), two further recordings of electrocardiogram,
lood pressure, and respiratory movements during fixed-rate
espiration were taken.
Venous blood samples were collected at baseline (before
nfusion) and 30 min after infusion, and were analyzed using
blood gas analyzer (IL 1640 system, Instrumentation
aboratory, Lexington, Massachusetts) in order to deter-
ine plasma potassium concentration.
ata analysis. All data were analyzed by an investigator
ho remained blinded to the study agent. The data seg-
ents were reviewed before heart rate variability analysis
nd if necessary edited to exclude ectopic and artifact
ignals. Data segments containing 1% of ectopic beats
ere discarded. RR intervals before and after any ectopic
eat were replaced by interpolation from the previous and
ollowing sinus RR intervals. Heart rate variability data were
nalyzed off-line using both the LabVIEW 5.0 software and
icrosoft Excel X (Microsoft Corporation, Seattle, Wash-
ngton). Each RR interval was assigned a value for systolic,
iastolic, and average blood pressure, and a value for
espiratory movement.
The RR intervals were analyzed in both the time and
requency domain as described previously (22). In brief,
tandard time domain measures of SDNN (standard devi-
tion of RR interval values), RMSSD (root mean square of
uccessive RR interval differences), and pNN50 (percentage
f successive RR interval differences exceeding 50 ms) were
alculated. SDNN expresses overall variability, whereas
MSSD and pNN50 assess high frequency or beat-to-beat
ariability, which is mediated primarily by the vagus nerve
23–25).
Power spectral analysis was performed on stationary time
eries using autoregressive modeling. The model order was
elected to minimize the Akaike information criterion. The
ower at each underlying frequency was quantified by
ecomposing the total variability signal according to the
ethod of Zetterburg. Powers at low frequency (LF, cen-
ered at 0.1 Hz) and at high frequency (HF, correspond-
ng to the observed respiratory frequency) were thus deter-
ined. Power was expressed in absolute and normalised
nits (nU) (power/total power 0.04 Hz) (26).
To assess baroreflex sensitivity by cross-spectral analysis,
he recordings of RR intervals and systolic blood pressure
ere interpolated (with a cubic spline) and then resampled
t 1 Hz to produce a uniform time base. A cross spectrum
f 256 samples was then analysed by fast Fourier transforms
ith the use of a Hanning window on successive overlap-
ing records of 64 samples each. Baroreflex sensitivity was
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Aldosterone Antagonism and Cardiac Vagal Control April 7, 2004:1270–5etermined by measurement of the alpha-index: the transfer
unction of variability in the systolic pressure signal to the
ariability in the RR interval. The alpha-index was calcu-
ated as the square root of the ratio of RR interval power to
ystolic spectral power in both the HF (alpha-HF) and LF
alpha-LF) bands. Data segments were accepted if a coher-
nce of 0.5 or greater was achieved between RR interval and
ystolic blood pressure traces. Because alpha-HF is deter-
ined as a frequency at which sympathetic influences are
ot effective, this index represents gain in the vagal limb of
he baroreflex (27).
Duplicate recordings were made at baseline and following
nfusion of either the vehicle control, or the active treat-
ent. Results were calculated as the mean of the two
ecordings.
tatistical analysis. Changes in the parameters from base-
ine values to post infusion were determined for potassium
anrenoate and for saline. Data were tested for normality of
istribution and the significance of the differences between
roups were determined using a two-tailed paired Student t
est for normally distributed data; otherwise the Wilcoxon
igned-rank test was used. Statistical significance was as-
umed at the 5% level (p  0.05). Values are expressed as
ean  standard error mean.
ESULTS
he frequency of metronomic breathing was within the
ange 0.18 to 0.22 Hz. The baseline values before admini-
tration of saline or potassium canrenoate for RR interval,
ean arterial pressure, measures of RR interval variability,
nd baroreflex sensitivity were not significantly different
Table 1). Infusion of potassium canrenoate had no signifi-
able 1. RR Interval, Mean Arterial Pressure Before, RR
nterval Variability, and Baroreflex Sensitivity (Alpha-Index) at
aseline (Before Infusion of Saline or Active Treatment With
otassium Canrenoate [K-Can]) (n  13)
Index
Control
Baseline
Active
Baseline Significance
R interval (ms) 932  35 941  37 NS
AP (mm Hg) 90  3 92  3 NS
ulse pressure (mm Hg) 63  3 62  3 NS
DNN (ms) 76  10 69  7 NS
MSSD (ms) 76  14 64  8 NS
NN50 (%) 39  6 35  6 NS
F power (ms2) 1,232  337 855  155 NS
F power (% nU) 27  5 24  4 NS
F power (ms2) 3,370  1,001 2,921  654 NS
F power (% nU) 60  5 65  4 NS
otal power (ms2) 6,963  1,855 5,354  961 NS
lpha-HF (ms/mm Hg) 19.2  2.3 20.3  2.5 NS
lpha-LF (ms/mm Hg) 12.8  1.8 11.3  1.3 NS
alues are mean  SEM.
HF  high frequency; LF  low frequency; MAP  mean arterial pressure; NS
no significance between control baseline and active baseline values; pNN50 
ercentage of successive RR interval differences exceeding 50 ms, RMSSD  root
ean square of successive RR interval differences; SDNN standard deviation of RR
nterval values.ant effect on baseline mean arterial pressure compared to fialine infusion (Table 2), but was associated with a signifi-
ant increase in RR interval duration (Table 2).
Heart rate variability assessed by SDNN was significantly
ncreased after aldosterone receptor blockade compared to
aline (Table 2). Measures of HF vagally mediated heart
ate variability in both the time and frequency domains were
lso significantly increased following potassium canrenoate
nfusion compared to saline. In the time domain both
MSSD and pNN50 were elevated by aldosterone receptor
lockade compared with control (Table 2). Power spectral
nalysis of the RR intervals revealed that with potassium
anrenoate, HF power was significantly increased, whereas
F power remained unchanged (Fig. 1, Table 2).
Cross-spectral analysis of RR interval and systolic blood
ressure variability was possible with all data sets (i.e.,
oherence was 0.05). Alpha-HF was greater following
ldosterone receptor blockade compared with saline infu-
ion, whereas alpha-LF remained unchanged (Table 2).
Baseline values for potassium concentrations were not
tatistically different (4.4  0.5 mmol/l pre-saline; 4.4 
.2 mmol/l pre-potassium canrenoate). The mean after
nfusion of saline (4.4  0.5 mmol/l) and potassium
anrenoate (4.4  0.2 mmol/l) remained unchanged.
ISCUSSION
cute administration of the aldosterone antagonist potas-
ium canrenoate results in an increase in HF measures of
eart rate variability and an increase in baroreflex sensitivity,
uggesting that aldosterone exerts a tonic inhibitory effect
n cardiac vagal control. Several studies have demonstrated
hat the diuretic response to potassium canrenoate does not
ccur until at least 2 h after intravenous administration
28,29), so it is unlikely that these results can be explained
y any change in circulating volume. Similarly, the results
annot be explained by changes in blood pressure or
otassium concentration, or by chronic effects on vascular
able 2. Change in RR Interval, Mean Arterial Pressure
MAP), RR Interval Variability, and Baroreflex Sensitivity
Alpha-Index) Following Control Infusion of Saline or Active
reatment With Potassium Canrenoate (K-Can) (n  13)
Index  Saline  K-Can p Value
R Interval (ms) 6  12 941  21 0.002
AP (mm Hg) 7  2 2  2 0.090
ulse pressure (mm Hg) 1  3 2  3 0.4
DNN (ms) 3  5 18  5 0.003
MSSD (ms) 2  5 20  6 0.005
NN50 (%) 0  4 15  4 0.003
F power (ms2) 219  184 337  282 0.657
F power (% nU) 3  2 4  4 0.137
F power (ms2) 44  424 1,354  762 0.040
F power (% nU) 3  3 3  4 0.180
otal power (ms2) 397  749 2,466  1,158 0.134
lpha-HF (ms/mm Hg) 0  1 4  1 0.034
lpha-LF (ms/mm Hg) 2  1 3  1 0.108
alues are mean  SEM.
Abbreviations as in Table 1.brosis and compliance at the arterial baroreceptors.
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hat we have demonstrated are consistent with the findings
f human study in which infusion of aldosterone caused an
mmediate reduction in baroreflex sensitivity (18). One
ossible mechanism of action of aldosterone could be a
irect effect on the arterial baroreceptors themselves. In
ogs, local infusion of aldosterone into the isolated carotid
inus caused a reduction in baroreceptor discharge, an effect
hat was abolished by the aldosterone antagonist spirono-
actone (30). Denudation of the carotid sinus endothelium
lso abolished the action of aldosterone. The authors con-
luded that aldosterone exerts inhibitory effects on the
aroreceptor by a mechanism dependent on endothelial cell
unction. More recently, an adverse effect of aldosterone on
ndothelial function consistent with a reduced bioavailabil-
ty of nitric oxide (NO) has been confirmed (31,32). Our
ndings might therefore be explained by improved barore-
eptor function as a result of inhibition of the actions of
ldosterone on vascular endothelial cell function.
A second explanation for our results is that aldosterone
xerts a tonic inhibitory effect on peripheral or central
ardiac vagal neuronal activity. Traditionally, mineralocor-
icoid receptors (MR) (cytoplasmic type I receptors) were
hought to be located exclusively in the distal tubule of the
idneys (33), but numerous studies have identified MRs
ithin the central nervous system as well as in myocardium
nd blood vessels. Centrally administered aldosterone has
een shown to increase blood pressure in rats, suggesting a
entral neurogenic action (34). Furthermore, direct admin-
stration of spironolactone into the central nervous system of
ats with chronic heart failure has been shown to improve
igure 1. Power spectral density plots showing the distribution of power
aseline and following saline or potassium canrenoate infusion, demonstrat
o significant change in low-frequency power (0.1 Hz) compared to conardiac autonomic control by reducing sympathetic outflow and improving the arterial baroreflex (35). These data
uggest that activation of mineralocorticoid receptors in the
entral nervous system plays an important role in the
mpaired cardiac autonomic function seen in heart failure
nd supports a central rather than peripheral nervous mech-
nism for the acute effects of potassium canrenoate.
Like other mineralocorticoids, aldosterone has long been
eld to exert its actions at a genomic level, affecting the
ranscription of messenger ribonucleic acid and subse-
uently protein synthesis. Over the last decade however,
onvincing evidence of a non-genomic, or direct effect of
ldosterone has become available (36). These nongenomic
ffects cause a rapid (5 min following intravenous aldo-
terone administration) rise in systemic vascular resistance,
hich is not due to sodium or water retention (37). Until
ecently it was the consensus that these nongenomic effects
re insensitive not only to inhibitors of transcription, but
lso to the classical mineralocorticoid receptor antagonists
ncluding canrenone. A recent study, however, has demon-
trated that RU28318, a weak competitor of the classic MR,
locks rapid effects of aldosterone. As this compound is
tructurally similar to the active metabolites of spironolac-
one and canrenoate, it is therefore plausible that canrenone
n our study was blocking rapid nongenomic effects of
ldosterone (38) upon the autonomic nervous system. A
apid effect of aldosterone within the autonomic nervous
ystem might also be mediated by an alteration in the NO
athway. The documented effects of aldosterone on the
ioavailability of endothelial NO leads us to speculate that
t may also reduce the synthesis and or bioavailability of
euronal NO. In our previous studies we have demonstrated
) against frequency (Hz). Representative spectral plots from a subject at
e increase in high-frequency power (0.2 Hz) after active treatment with(ms2
ing thpowerful facilitatory effect of NO on human cardiac
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Aldosterone Antagonism and Cardiac Vagal Control April 7, 2004:1270–5utonomic control, a result consistent with a large body of
ublished work that supports a vagotonic role for NO (39).
hus, a further mechanism by which aldosterone may exert
n acute inhibitory action on cardiac vagal control may be by
educing the bioavailability of NO within the cardiac
utonomic nervous system.
Finally, aldosterone is also known to exert a weak
drenergic action. In healthy humans aldosterone blunted
he blood pressure-lowering effect of a beta-blocking agent,
uggesting that an acute nongenomic influence on adrener-
ic activity (40). It is thus also plausible that any inhibitory
nfluence of aldosterone on cardiac vagal activity might not
ccur via the well-described inhibitory action of the sym-
athetic nervous system on cardiac vagal activity (41,42).
onversely, vagal enhancement by aldosterone receptor
ntagonists might in part result from reduced sympathetic
ctivity.
In conclusion, this study demonstrates that acute treat-
ent with an aldosterone antagonist improves cardiac vagal
ontrol in healthy volunteers. The improved cardiac vagal
one that we have demonstrated in healthy volunteers may
e of clinical significance in patients with heart failure who,
ven at an early stage of their disease, have profound
utonomic dysfunction (43) and in whom levels of aldoste-
one are often elevated despite treatment with angiotensin-
onverting enzyme inhibitors. Patients who demonstrate
ldosterone “escape” from angiotensin-converting enzyme
nhibitor therapy are known to have a particularly poor
rognosis (44), and the adverse actions of aldosterone on
ardiac autonomic control may contribute to this. The
linical significance of the relationship between activation of
he renin-angiotensin system and impaired cardiac auto-
omic control was reconfirmed recently by the demonstra-
ion that plasma renin is an important determinant of
ardiac vagal control in hypertension (45). Our results
uggest that treatment with aldosterone antagonists im-
roves cardiac autonomic control via rapid nongenomic
ffects that are most likely exerted within the central nervous
ystem.
tudy limitations. Although intra-arterial blood pressure
easurement is the most accurate means of beat to beat
lood pressure monitoring, the “Portapres” that we em-
loyed uses infrared plethysmography and a fast-acting
ervo to “volume clamp” finger arteries and has been found
o provide accurate beat-to-beat blood pressure measure-
ent (46). Intra-arterial recording was not employed in
rder to minimize patient discomfort and associated adverse
utonomic effects. For similar reasons we did not use a
rinary catheter. Although a small diuresis in response to
otassium canrenoate cannot therefore be excluded, we feel
hat any such effect, if present, was probably small.
Finally, we did not demonstrate directly the aldosterone
eceptor antagonism of potassium canrenoate in this study.
he single dose used has, however, been shown to result inffective aldosterone antagonism in healthy humans (21,47).eprint requests and correspondence: Dr. Ashesh N. Buch,
esearch Fellow in Cardiology, Department of Cardiovascular
edicine, Queen Elizabeth Hospital, Edgbaston, Birmingham
15 2TH, United Kingdom. E-mail: asheshbuch@hotmail.com.
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